BRCA1 and prostate cancer: Nonetheless, this study represents a meaningful advancement towards the clinical translation of ddPCR-based BRCA1/2 CNV detection, and these integrated tools may ultimately support the development of clinically actionable CNV biomarkers in prostate cancer and other malignancies.